PIONEER REAL Japan: Primary results from a multicenter, prospective, real‐world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice

Documenti analoghi

• A multicenter, prospective, real‐world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice ( PIONEER REAL Japan): Subgroup analyses
  di: Daisuke Yabe, et al.
  Pubblicazione: (2025)
• PIONEER REAL Japan: Baseline characteristics of a multicenter, prospective, real‐world study of oral semaglutide in adults with type 2 diabetes in clinical practice in Japan
  di: Ryo Suzuki, et al.
  Pubblicazione: (2024)
• Safety and effectiveness of tofogliflozin in Japanese people with type 2 diabetes: A multicenter prospective observational study in routine clinical practice
  di: Yuichiro Yamada, et al.
  Pubblicazione: (2024)
• Real‐world safety profile of once‐weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real‐world Evidence (SURE) programme
  di: Jean‐François Yale, et al.
  Pubblicazione: (2024)
• A consensus statement from the Japan Diabetes Society: A proposed algorithm for pharmacotherapy in people with type 2 diabetes – 2nd edition (English version)
  di: Ryotaro Bouchi, et al.
  Pubblicazione: (2024)